ImmunoGen and Millennium Sign Exclusive Product License
MLN591 is directed towards the extracellular domain of Prostate Specific Membrane Antigen (PSMA), which is expressed by virtually all prostate tumors. DM1 is a highly potent cytotoxic agent developed by ImmunoGen. ImmunoGen's TAP technology couples the Company's proprietary anti-cancer agents with tumor- targeting antibodies to achieve antibody-directed killing of cancer cells.
"This product license represents the next step in our collaboration in the development of a TAP product comprised of Millennium's MLN591 and our DM1," said Mitchel Sayare, Ph.D., Chairman and CEO. "We are delighted with Millennium's stated goal to initiate clinical trials with MLN591DM1 this year and we will be manufacturing product for Millennium for this purpose."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.